Literature DB >> 3668568

Cognitive concomitants of dopamine system stimulation in parkinsonian patients.

E Mohr1, G Fabbrini, S Ruggieri, P Fedio, T N Chase.   

Abstract

Verbal, visuospatial and motor functions were studied in eight Parkinsonian patients both during levodopa stimulated and unstimulated state and in eight matched, untreated, healthy controls. Profound changes in patients' motor status were accompanied by relatively selective effects on delayed verbal memory, a function which was also most impaired compared with controls. With dopaminomimetic therapy, tests of delayed verbal memory consistently improved, but did not reach control performance levels. These results could indicate a functional impairment in the mesocortical dopamine system, which can be attenuated, but not entirely corrected, by dopaminomimetic therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3668568      PMCID: PMC1032354          DOI: 10.1136/jnnp.50.9.1192

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  24 in total

1.  Reversal by L-dopa of impaired learning due to destruction of the dopaminergic nigro-neostriatal projection.

Authors:  A P Zis; H C Fibiger; A G Phillips
Journal:  Science       Date:  1974-09-13       Impact factor: 47.728

2.  Reversal of the reserpine-induced suppression of the conditioned avoidance response by L-dopa: correlation of behavioral and biochemical differences in two strains of mice.

Authors:  L S Seiden; D D Peterson
Journal:  J Pharmacol Exp Ther       Date:  1968-02       Impact factor: 4.030

3.  Intellectual changes associated with levodopa therapy.

Authors:  M J Meier; W E Martin
Journal:  JAMA       Date:  1970-07-20       Impact factor: 56.272

4.  Neurochemistry of Parkinson's disease: relation between striatal and limbic dopamine.

Authors:  K S Price; I J Farley; O Hornykiewicz
Journal:  Adv Biochem Psychopharmacol       Date:  1978

5.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

6.  Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey.

Authors:  T J Brozoski; R M Brown; H E Rosvold; P S Goldman
Journal:  Science       Date:  1979-08-31       Impact factor: 47.728

7.  Parkinsonism: effects of levodopa treatment on concept formation.

Authors:  F P Bowen; R S Kamienny; M M Burns; M Yahr
Journal:  Neurology       Date:  1975-08       Impact factor: 9.910

8.  Levodopa's awakening effect on patients with Parkinsonism.

Authors:  G G Marsh; C M Markham; R Ansel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1971-06       Impact factor: 10.154

9.  Visuoperceptive deficits in long-term alcoholics and alcoholics with Korsakoff's psychosis.

Authors:  N Kapur; N Butters
Journal:  J Stud Alcohol       Date:  1977-11

10.  Levodopa and psychometric test performance in parkinsonism-5 years later.

Authors:  M Riklan; W Whelihan; T Cullinan
Journal:  Neurology       Date:  1976-02       Impact factor: 9.910

View more
  8 in total

1.  Relations between on-off phenomena and cognitive functions in Parkinson disease.

Authors:  G Meco; V Bonifati; L Bedini; A Bellatreccia; N Vanacore; A Franzese
Journal:  Ital J Neurol Sci       Date:  1991-02

Review 2.  Deterioration of dopaminergic pathways and alterations in cognition and motor functions.

Authors:  B Dubois; B Pillon; Y Agid
Journal:  J Neurol       Date:  1992       Impact factor: 4.849

3.  Cognitive improvement during Tolcapone treatment in Parkinson's disease.

Authors:  M Gasparini; E Fabrizio; V Bonifati; G Meco
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

4.  Evoked potentials, reaction time and cognitive performance in on and off phases of Parkinson's disease.

Authors:  S E Starkstein; M Esteguy; M L Berthier; H Garcia; R Leiguarda
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-03       Impact factor: 10.154

5.  SPECT neuroimaging and neuropsychological functions in different stages of Parkinson's disease.

Authors:  Anna Paschali; Lambros Messinis; Odysseas Kargiotis; Velissarios Lakiotis; Zinovia Kefalopoulou; Costantinos Constantoyannis; Panagiotis Papathanasopoulos; Pavlos Vassilakos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-10       Impact factor: 9.236

Review 6.  Neurotransmitter replacement therapy in Alzheimer's disease.

Authors:  E Mohr; T Mendis; I N Rusk; J D Grimes
Journal:  J Psychiatry Neurosci       Date:  1994-01       Impact factor: 6.186

Review 7.  Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease.

Authors:  J Kulisevsky
Journal:  Drugs Aging       Date:  2000-05       Impact factor: 3.923

8.  Dopamine does not appear to affect mental rotation in Parkinson's disease.

Authors:  Gregory P Crucian; Sheyan Armaghani; Avan Armaghani; Paul S Foster; David W Burks; Barry Skoblar; Valeria Drago; Kenneth M Heilman
Journal:  J Mov Disord       Date:  2014-10-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.